Table 2.

Selectivity profile of the monoamine reuptake inhibitors studied in idiopathic PD and animal models of PD.

Transporter	Compound
SERT	Citalopram, clomipramine, duloxetine, escitalopram, fenfluramine, fluoxetine, fluvoxamine, imipramine, paroxetine, R-MDMA, sertraline, trazodone, trimipramine, UWA-122, and venlafaxine
SERT = NET	Amitriptyline, milnacipran
NET	Amoxapine, amphetamine, atomoxetine, desipramine, L-amphetamine, maprotiline, mazindol, mianserin, mirtazapine, nisoxetine, nortriptyline, and reboxetine
DAT	Amineptine, modafinil, SEP-228,791, and vanoxerine
DAT = NET	Benztropine, brasofensine, bupropion, cocaine, D-amphetamine, methamphetamine, methylphenidate, nomifensine, and S,S-hydroxybupropion
DAT = SERT	UWA-101, UWA-121
DAT = SERT = NET	BTS 74,398, MDMA, nefazodone, S-MDMA, and tesofensine
SERT enhancer	Tianeptine

D-: dextro; DAT: dopamine transporter; L-: levo; MDMA: 3,4-methylenedioxymethamphetamine; NET: noradrenaline transporter; PD: Parkinson's disease; R-: rectus; S-: sinister; SERT: serotonin transporter.

In this table, all of the compounds were attributed a primary affinity based on the highest potency value displayed in Table 1. Compounds with more than 5-fold selectivity for a monoamine transporter were considered selective for this transporter (see Section 2).